Thymidine kinase and thymidine phosphorylase level as the main predictive parameter for sensitivity to TAS-102 in a mouse model

Oncology Reports

Volumn 11, Issue 2, 2004, Pages 381-387

  Emura, Tomohiro ^a   Nakagawa, Fumio ^a   Fujioka, Akio ^a   Ohshimo, Hideyuki ^a   Kitazato, Kenji ^a  

^a TAIHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Prediction; TAS 102; Thymidine kinase; Thymidine phosphorylase; Thymidine rescue

Indexed keywords

ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; TAS 102; THYMIDINE KINASE; THYMIDINE PHOSPHORYLASE; THYMIDYLATE SYNTHASE; TRIFLURIDINE; URACIL;

ANIMAL; ARTICLE; BAGG ALBINO MOUSE; CELL DIVISION; DRUG COMBINATION; DRUG EFFECT; HEAD AND NECK TUMOR; HUMAN; MALE; METABOLISM; MOUSE; MOUSE MUTANT; NUDE MOUSE; PANCREAS TUMOR; PATHOLOGY; STOMACH TUMOR; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL DIVISION; DRUG COMBINATIONS; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MICE, SCID; PANCREATIC NEOPLASMS; STOMACH NEOPLASMS; THYMIDINE KINASE; THYMIDINE PHOSPHORYLASE; THYMIDYLATE SYNTHASE; TRANSPLANTATION, HETEROLOGOUS; TRIFLURIDINE; URACIL;

EID: 3242813157     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.11.2.381     Document Type: Article

References (46)

1. Heidelberger C, Parsons DG and Remy DC: The synthesis of 5-trifluoromethyluracil and 5-trifluoromethyl-2′deoxyuridine. J Am Chem Soc 84: 3597-3598, 1962.
2. Heidelberger C, Parsons DG and Remy DC: Synthesis of 5-trifluoromethyl- 2′-deoxyuridine. J MedChem 7: 1-5, 1964.
3. Ansfield FJ and Ramirez G: Phase I and II studies of 2′-deoxy-5- (trifluoromethyl)-uridine (NSC-75520). Cancer Chemother Rep 55: 205-208, 1971.
4. Dexter DL, Wolberg WH, Ansfield FJ, Helson L and Heidelberger C: The clinical pharmacology of 5-trifluoromethyl-2′-deoxyuridine. Cancer Res 32: 247-253, 1972.
5. Eckstein JW, Foster PG, Finer-Moore J, Wataya Y and Santi DV: Mechanism-based inhibition of thymidylate synthase by 5-(trifluoromethyl)- 2′-deoxyuridine 5′-monophosphate. Biochemistry 33: 15086-15094, 1994.
6. Santi DV and Sakai TT: Thymidylate synthetase. Model studies of inhibition by 5-trifluoromethyl-2′-deoxyuridylic acid. Biochemistry 10: 3598-3607, 1971.
7. Fujiwara Y, Oki T and Heidelberger C: Fluorinated pyrimidines. XXXVII. Effects of 5-trifluoromethyl-2′-deoxyuridine on the synthesis of deoxyribonucleic acid of mammalian cells in culture. Mol Pharmacol 6: 273-280, 1970.
8. Fujiwara Y and Heidelberger C; Fluorinated pyrimidines. 38. The incorporation of 5-trifluoromethyl-2′-deoxyuridine into the deoxyribonucleic acid of vaccinia virus. Mol Pharmacol 6: 281-291, 1970.
9. Gottschling H and Heidelberger C: Fluorinated pyrimidines. XIX. Some biological effect of 5-trifluoromethyl-uracil and 5-trifluoromethyl-2′- deoxyuridine on Escherischia coli and bacteriophage T4B. J Mol Biol 7: 541-560, 1963.
10. Szybalski W, Cohn NK and Heidelberger C: Effects of 5-trifluoromethyl- 2′-deoxyuridine (F3dTdR) on the biochemical and radiological properties of human cells. FASEB 22: p532, 1963.
11. Emura T, Nakagawa F, Fujioka A, Ohshimo H, Yokogawa T, Okabe H and Kitazato K: An optimal dosing schedule for a novel combination antimetabolite, TAS-102, based on its intracellular metabolism and its incorporation into DNA. Int J Mol Med 13: 249-255, 2004.
12. Bresnick E and Williams SS: Effects of 5-trifluoromethyldeoxyuridine upon deoxythymidine kinase. Biochem Pharmacol 16: 503-507, 1967.
13. Tatsumi K, Fukushima M, Shirasaka T and Fujii S: Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extracts. Jpn J Cancer Res 78: 748-755, 1987. (Pubitemid 17132408)
14. Romain S, Christensen II, Chinot O, Balslev I, Rose C, Martin PM and Thorpe SM: Prognostic value of cytosolic thymidine kinase activity as a marker of proliferation in breast cancer. Int J Cancer 61: 7-12, 1995.
15. Pestalozzi BC, McGinn CJ, Kinsella TJ, Drake J C, Glennon MC, Allegra CJ and Johnston PG: Increased thymidylate synthase protein levels are principally associated with proliferation but not cell cycle phase in asynchronous human cancer cells. Br J Cancer 71: 1151-1157, 1995.
16. Broet P, Romain S, Daver A, Ricolleau G, Quillien V, Rallet A, Asselain B, Martin PM and Spyratos E: Thymidine kinase as a proliferative marker: clinical relevance in 1,692 primary breast cancer patients. J Clin Oncol 19: 2778-2787, 2001. (Pubitemid 32538185)
17. Kit S: Thymidine kinase, DNA synthesis and cancer: Mol Cell Biochem 11: 161-182, 1976.
18. Bourtourault M, Mahoudo H, Haras D, Samperez S and Jouan P: Stimulation by estradiol-17 beta of thymidine kinase activity in the rat uterus. J Steroid Biochem 21: 613-620, 1984. (Pubitemid 15194227)
19. Kauffman MG and Kelly TJ: Cell cycle regulation of thymidine kinase: residues near the carboxyl terminus are essential for the specific degradation of the enzyme at mitosis. Mol Cell Biol 11: 2538-2546, 1991. (Pubitemid 21895633)
20. Johnson LF, Rao LG and Muench AJ: Regulation of thymidine kinase enzyme level in serum-stimulated mouse 3T6 fibroblasts. Exp Cell Res 138: 79-85, 1982. (Pubitemid 12079753)
21. Coppock DL and Pardee AB: Control of thymidine kinase mRNA during the cell cycle. Mol Cell Biol 7: 2925-2932, 1987.
22. Sherley JL and Kelly TJ: Regulation of human thymidine kinase during the cell cycle. J Biol Chem 263: 8350-8358, 1988.
23. Ito M and Conrad SE: Independent regulation of thymidine kinase mRNA and enzyme levels in serum-stimulated cells. J Biol Chem 265: 6954-6960, 1990.
24. Jenh CH, Geyer PK and Johnson LF:. Control of thymidylate synthase mRNA content and gene transcription in an over-producing mouse cell line. Mol Cell Biol 5: 2527-2532, 1985. (Pubitemid 15249536)
25. Hashimoto Y, Shiotani T, Eble JN, Glover JL and Weber G: Increased thymidylate synthase (EC 2.1.1.45) activity in normal and neoplastic proliferation. Cancer Biochem Biophys 10: 1-10, 1988.
26. Jenh CH, Rao LG and Johnson LF: Regulation of thymidylate synthase enzyme synthesis in 5-fluorodeoxyuridine-resistant mouse fibroblasts during the transition from the resting to growing state. J Cell Physiol 122: 149-154, 1985. (Pubitemid 15177240)
27. Xu YZ and Plunkett W: Regulation of thymidine kinase and thymidylate synthase in intact human lymphoblast CCRF-CEM cells. J Biol Chem 268: 22363-22368 1993.
28. Chu E and Allegra CJ: Mechanisms of clinical resistance to 5-fluorouracil chemotherapy. Cancer Treat Res 87: 175-195, 1996.
29. Copur S, Aiba K, Drake JC, Allegra CJ and Chu E: Thymidylate synthase gene amplification in human colon cancer cell lines resistant to 5-fluorouracil. Biochem Pharmacol 49: 1419-1426, 1995.
30. Johnston PG, Lenz HJ, Leichman CG, Danenberg KD, Allegra CJ, Danenberg PV and Leichman L: Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 55: 1407-1412, 1995.
31. Lenz HJ, Leichman CG, Danenberg KD, Danenberg PV, Groshen S, Cohen H, Laine L, Crookes P, Silberman H, Baranda J, Garcia Y, Li J and Leichman L: Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival. J Clin Oncol 14: 176-182, 1996. (Pubitemid 26020011)
32. Aschele C, Debernardis D, Casazza S, Antonelli G, Tunesi G, Baldo C, Lionetto R, Maley F and Sobrero A: Immunohistochemical quantitation of thymidylate synthase expression in colorectal cancer metastases predicts for clinical outcome to fluorouracil-based chemotherapy. J Clin Oncol 17: 1760-1770, 1999. (Pubitemid 29269245)
33. Clark JL, Berger SH, Mittelman A and Berger FG: Thymidylate synthase gene amplification in a colon tumor resistant to fluoropyrimidine chemotherapy. Cancer Treat Rep 71: 261-265, 1987. (Pubitemid 17051726)
34. Johnston PG, Fisher ER, Rockette HE, Fisher B, Wolmark N, Drake JC, Chabner BA and Allegra CJ: The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J Clin Oncol 12: 2640-2647, 1994. (Pubitemid 24379651)
35. Murakami Y, Kazuno H, Emura T, Tsujimoto H, Suzuki N and Fukushima M: Different mechanisms of acquired resistance to fluorinated pyrimidines in human colorectal cancer cells. Int J Oncol 17: 277-283, 2000.
36. Collie-Duguid ES, Johnston SI, Boyce L, Smith N, Cowieson A, Cassidy J, Murray GI and McLeod HL: Thymidine phosphorylase and dihydropyrimidine dehydrogenase protein expression in colorectal cancer. Int J Cancer 94: 297-301, 2001. (Pubitemid 32911427)
37. Katsumata K, Sumi T, Yamashita S, Takahashi S, Mori M, Baba T, Murohashi T, Nagashima K, Ashizawa T, Yamamoto K, Koyanagi Y and Katoh K: The significance of thymidine phosphorylase expression in colorectal cancer. Oncol Rep 8: 127-130, 2001. (Pubitemid 33758214)
38. Mimori K, Matsuyama A, Yoshinaga K, Yamashita K, Masuda T, Inoue H, Ueo H and Mori M: Localization of thymidine phosphorylase expression in colorectal carcinoma tissues by in situ RT-PCR assay. Oncology 62: 327-332, 2002. (Pubitemid 34914102)
39. Higley B, Oakes I, De Merio J and Giles GR: Pyrimidine nucleoside phosphorylase activity in tumour and matched normal gastrointestinal mucosa. Gut 23: 1072-1076, 1982. (Pubitemid 13196635)
40. Yoshimura A, Kuwazuru Y, Fumkawa T, Yoshida H, Yamada K and Akiyama S: Purification and tissue distribution of human thymidine phosphorylase; high expression in lymphocytes, reticulocytes and tumors. Biochim Biophys Acta 1034: 107-113, 1990. (Pubitemid 20114807)
41. Luccioni C, Beaumatin J, Bardot V and Lefrancois D: Pyrimidine nucleotide metabolism in human colon carcinomas: comparison of normal tissues, primary tumors and xenografts. Int J Cancer 58: 517-522, 1994. (Pubitemid 24268092)
42. Fujiwaki R, Hata K, Moriyama M, Iwanari O, Katabuchi H, Okamura H and Miyazaki K: Clinical value of thymidine kinase in patients with cervical carcinoma. Oncology 61: 47-54, 2001. (Pubitemid 32727587)
43. O'Neill KL, McKelvey VJ, Hoper M, Monteverde H, Odling-Smee GW, Logan H, Abram WP and McKenna PG: Breast tumour thymidine kinase levels and disease recurrence. Med Lab Sci 49: 244-247, 1992. (Pubitemid 23020746)
44. O'Neill KL, Hoper M and Odling-Smee GW: Can thymidine kinase levels in breast tumors predict disease recurrence? J Natl Cancer Inst 84: 1825-1828, 1992.
45. Jacobsson B, Albertioni F and Eriksson S: Deoxynucleoside anabolic enzyme levels in acute myelocytic leukemia and chronic lymphocytic leukemia cells. Cancer Lett 165: 195-200, 2001. (Pubitemid 32244177)
46. Sadamori N, Ichiba M, Mine M, Hakariya S, Hayashibara T, Itoyama T, Nakamura H, Tomonaga M and Hayashi K: Clinical significance of serum thymidine kinase in adult T-cell leukaemia and acute myeloid leukaemia. Br J Haematol 90: 100-105, 1995.